fluorouracil has been researched along with megestrol acetate in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Foitl, DR; Hyman, G; Lefkowitch, JH | 1 |
| Cohen, SC; Gregory, EJ; Mims, CH; Oines, DW | 1 |
| Baker, TR; Cornelison, TL; Driscoll, DL; Piver, MS | 1 |
| Bewsher, C; Manyam, V; Marsh, RW; Youngblood, M | 1 |
| Karakuzu, A; Koc, M; Ozdemir, S | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Baby, T; Chennazhi, KP; Jayakumar, R; Rejinold, NS | 1 |
1 trial(s) available for fluorouracil and megestrol acetate
| Article | Year |
|---|---|
Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Melphalan; Middle Aged; Prospective Studies; Survival Rate | 1995 |
13 other study(ies) available for fluorouracil and megestrol acetate
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Breast Neoplasms; Cholestasis, Intrahepatic; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Humans; Jaundice; Mastectomy, Radical; Megestrol; Megestrol Acetate; Methotrexate; Prednisone; Vincristine | 1989 |
Megestrol acetate therapy for advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Fluorouracil; Humans; Male; Megestrol; Megestrol Acetate; Menopause; Methotrexate; Receptors, Estrogen; Receptors, Progesterone | 1985 |
Circadian rhythm modulated 5-FUdR infusion with Megace in the treatment of advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Megestrol; Megestrol Acetate; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 1994 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Fatal Outcome; Fluorouracil; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Mastectomy, Radical; Megestrol Acetate; Middle Aged; Paclitaxel; Palliative Care; Skin Neoplasms | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Multi Drug Loaded Thermo-Responsive Fibrinogen-graft-Poly(N-vinyl Caprolactam) Nanogels for Breast Cancer Drug Delivery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caprolactam; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Diffusion; Fibrinogen; Fluorouracil; Humans; Hydrogels; Megestrol Acetate; Nanocapsules; Particle Size; Polymers; Receptors, Vitronectin; Temperature | 2015 |